Date:8/14/2009

3,100 Total current liabilities 4,480 4,685 Capital lease obligation - non-current 7 Equipment loan - non-current 470 271 Deferred revenue - non-current 1,667 617 Total liabilities 6,624 5,573 Stockholders' Equity: Common stock, $0.01 par value; 65,000 and 65,000 shares authorized at December 31, 2008 and June 30, 2009, respectively, 21,471 and 21,980 issued and outstanding at December 31, 2008 and June 30, 2009, respectively 215 220 Additional paid-in capital 33,718 34,434 Accumulated other comprehensive income (loss) (3) Accumulated deficit during development stage (26,588) (27,195) Total stockholders' equity 7,345 7,456 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $13,969 $13,029

                         NOVABAY PHARMACEUTICALS, INC
                    (formerly NovaCal Pharmaceuticals Inc.)
                        (a developmental stage company)

                    CONSOLIDATED STATEMENTS OF OPERATIONS
                    (in thousands, except per share data)

                                                                   Cumulative
                                                                  Period from
                                                                  July 1, 2002
                                                                    (date of
                                                                   development
                                                                     stage
                        Three Months Ended     Six Months 
'/>"/>
SOURCE  NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 
Related biology technology :

1. NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development
2. NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
3. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
4. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
5. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
6. Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
7. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
8. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
9. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
11. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States